Comments

Jazz Pharmaceuticals

JAZZNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$109.01
00.00%
Pre-Market: Jul 19, 4:00 PM EDT
15 minutes delayed
Q2 2024 Earnings in 9 days from now on Wed Jul 31st, after the market close
Jazz Pharmaceuticals (JAZZ) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesGovernment TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$230.00
Lowest Price Target1
$113.00
Consensus Price Target1
$187.78

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock, Analyst Ratings, Price Targets, Forecasts

Jazz Pharmaceuticals PLC has a consensus price target of $187.78 based on the ratings of 19 analysts. The high is $230 issued by Stifel on March 15, 2024. The low is $113 issued by UBS on July 2, 2024. The 3 most-recent analyst ratings were released by Morgan Stanley, UBS, and Needham on July 12, 2024, July 2, 2024, and June 20, 2024, respectively. With an average price target of $157.67 between Morgan Stanley, UBS, and Needham, there's an implied 44.64% upside for Jazz Pharmaceuticals PLC from these most-recent analyst ratings.

Analyst Trends and Forecast
4
1
Mar
1
Apr
1
May
0
0
0
0
Jun
2
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Morgan Stanley
UBS
Needham
Goldman Sachs
HC Wainwright & Co.

1calculated from analyst ratings

Analyst Ratings for Jazz Pharmaceuticals

Buy NowGet Alert
07/12/2024Buy Now37.6%Morgan Stanley
Jeffrey Hung
$160 → $150MaintainsEqual-WeightGet Alert
07/02/2024Buy Now3.66%UBS
Ashwani Verma
$117 → $113MaintainsNeutralGet Alert
06/20/2024Buy Now92.64%Needham
Ami Fadia
$222 → $210MaintainsBuyGet Alert
06/05/2024Buy Now55.03%Goldman Sachs
Madhu Kumar
 → $169Initiates → BuyGet Alert
05/03/2024Buy Now83.47%HC Wainwright & Co.
Oren Livnat
 → $200ReiteratesBuy → BuyGet Alert
05/03/2024Buy Now83.47%Barclays
Balaji Prasad
$230 → $200MaintainsOverweightGet Alert
05/02/2024Buy Now103.65%Needham
Ami Fadia
 → $222ReiteratesBuy → BuyGet Alert
04/10/2024Buy Now65.12%Cantor Fitzgerald
Charles Duncan
 → $180ReiteratesOverweight → OverweightGet Alert
03/22/2024Buy Now65.12%Cantor Fitzgerald
Charles Duncan
 → $180ReiteratesOverweight → OverweightGet Alert
03/22/2024Buy Now74.3%JP Morgan
Jessica Fye
$170 → $190MaintainsOverweightGet Alert
03/20/2024Buy Now101.82%Needham
Ami Fadia
 → $220ReiteratesBuy → BuyGet Alert
03/20/2024Buy Now83.47%Truist Securities
Joon Lee
 → $200ReiteratesBuy → BuyGet Alert
03/20/2024Buy Now72.46%Piper Sandler
David Amsellem
$171 → $188ReiteratesOverweight → OverweightGet Alert
03/15/2024Buy Now110.99%Stifel
Annabel Samimy
$225 → $230MaintainsBuyGet Alert
03/14/2024Buy Now83.47%HC Wainwright & Co.
Oren Livnat
$204 → $200MaintainsBuyGet Alert
03/01/2024Buy Now110.99%Barclays
Balaji Prasad
$235 → $230MaintainsOverweightGet Alert
03/01/2024Buy Now20.17%UBS
Ashwani Verma
$135 → $131MaintainsNeutralGet Alert
02/29/2024Buy Now65.12%Cantor Fitzgerald
Charles Duncan
 → $180ReiteratesOverweight → OverweightGet Alert
02/29/2024Buy Now78.88%RBC Capital
Gregory Renza
 → $195ReiteratesOutperform → OutperformGet Alert
02/29/2024Buy Now55.95%JP Morgan
Jessica Fye
$180 → $170MaintainsOverweightGet Alert
02/29/2024Buy Now101.82%Needham
Ami Fadia
$225 → $220MaintainsBuyGet Alert
01/29/2024Buy Now115.58%Barclays
Balaji Prasad
$240 → $235MaintainsOverweightGet Alert
01/03/2024Buy Now46.78%Baird
Joel Beatty
 → $160Initiates → OutperformGet Alert
12/04/2023Buy Now83.47%Truist Securities
Joon Lee
 → $200ReiteratesBuy → BuyGet Alert
11/29/2023Buy Now106.4%Needham
Ami Fadia
 → $225ReiteratesBuy → BuyGet Alert
11/27/2023Buy Now23.84%UBS
Ashwani Verma
$170 → $135DowngradeBuy → NeutralGet Alert
11/09/2023Buy Now75.21%RBC Capital
Gregory Renza
$200 → $191MaintainsOutperformGet Alert
11/09/2023Buy Now106.4%Needham
Ami Fadia
$226 → $225MaintainsBuyGet Alert
09/29/2023Buy Now—Raymond James
Gary Nachman
—Initiates → Market PerformGet Alert
08/22/2023Buy Now65.12%Cantor Fitzgerald
Brandon Folkes
 → $180ReiteratesOverweight → OverweightGet Alert
08/14/2023Buy Now65.12%Cantor Fitzgerald
Brandon Folkes
$210 → $180MaintainsOverweightGet Alert
08/11/2023Buy Now87.14%HC Wainwright & Co.
Oren Livnat
 → $204ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now99.06%B of A Securities
Jason Gerberry
$204 → $217MaintainsBuyGet Alert
08/10/2023Buy Now84.39%RBC Capital
Gregory Renza
$203 → $201MaintainsOutperformGet Alert
08/10/2023Buy Now107.32%Needham
Ami Fadia
 → $226ReiteratesBuy → BuyGet Alert
08/07/2023Buy Now107.32%Needham
Ami Fadia
 → $226ReiteratesBuy → BuyGet Alert
07/11/2023Buy Now71.54%Morgan Stanley
Jeffrey Hung
$187 → $187ReiteratesEqual-Weight → Equal-WeightGet Alert
06/05/2023Buy Now107.32%Needham
Ami Fadia
 → $226ReiteratesBuy → BuyGet Alert
05/30/2023Buy Now107.32%Needham
Ami Fadia
$212 → $226ReiteratesBuy → BuyGet Alert
05/15/2023Buy Now87.14%HC Wainwright & Co.
Oren Livnat
 → $204ReiteratesBuy → BuyGet Alert
05/15/2023Buy Now94.48%Needham
Ami Fadia
 → $212ReiteratesBuy → BuyGet Alert
05/11/2023Buy Now85.3%RBC Capital
Gregory Renza
$207 → $202MaintainsOutperformGet Alert
05/11/2023Buy Now94.48%Needham
Ami Fadia
$205 → $212MaintainsBuyGet Alert
03/06/2023Buy Now87.14%HC Wainwright & Co.
Oren Livnat
 → $204Reiterates → BuyGet Alert
03/03/2023Buy Now94.48%Goldman Sachs
Madhu Kumar
$190 → $212MaintainsBuyGet Alert
03/02/2023Buy Now88.06%Needham
Ami Fadia
$210 → $205MaintainsBuyGet Alert
12/09/2022Buy Now74.3%Goldman Sachs
Madhu Kumar
$192 → $190UpgradeNeutral → BuyGet Alert
11/10/2022Buy Now76.13%Goldman Sachs
Madhu Kumar
$170 → $192MaintainsNeutralGet Alert
11/10/2022Buy Now89.89%RBC Capital
Gregory Renza
$206 → $207MaintainsOutperformGet Alert
11/10/2022Buy Now90.81%Needham
Ami Fadia
$210 → $208MaintainsBuyGet Alert
09/29/2022Buy Now55.95%Goldman Sachs
Madhu Kumar
$148 → $170MaintainsNeutralGet Alert
09/21/2022Buy Now35.77%Goldman Sachs
Madhu Kumar
$192 → $148MaintainsNeutralGet Alert
08/04/2022Buy Now72.46%BMO Capital
Gary Nachman
$185 → $188MaintainsOutperformGet Alert
08/04/2022Buy Now71.54%Morgan Stanley
Jeffrey Hung
$174 → $187MaintainsEqual-WeightGet Alert
08/04/2022Buy Now75.21%UBS
Ashwani Verma
$194 → $191MaintainsBuyGet Alert
08/04/2022Buy Now92.64%SVB Leerink
Marc Goodman
$200 → $210MaintainsOutperformGet Alert
06/14/2022Buy Now77.97%UBS
Ashwani Verma
 → $194Initiates → BuyGet Alert
05/05/2022Buy Now90.81%RBC Capital
Gregory Renza
$210 → $208MaintainsOutperformGet Alert
05/05/2022Buy Now77.05%Piper Sandler
David Amsellem
$197 → $193MaintainsOverweightGet Alert
04/06/2022Buy Now79.8%Goldman Sachs
Madhu Kumar
$202 → $196DowngradeBuy → NeutralGet Alert
03/03/2022Buy Now97.23%HC Wainwright & Co.
Oren Livnat
$210 → $215MaintainsBuyGet Alert
03/02/2022Buy Now80.72%Piper Sandler
David Amsellem
$209 → $197MaintainsOverweightGet Alert
03/02/2022Buy Now96.31%RBC Capital
Gregory Renza
$216 → $214MaintainsOutperformGet Alert
12/20/2021Buy Now83.47%SVB Leerink
Marc Goodman
—MaintainsOutperformGet Alert
12/17/2021Buy Now97.23%Needham
Ami Fadia
—MaintainsBuyGet Alert
10/08/2021Buy Now59.62%Morgan Stanley
Jeffrey Hung
—MaintainsEqual-WeightGet Alert
10/05/2021Buy Now83.47%Citigroup
Navann Ty
—Initiates → BuyGet Alert
09/23/2021Buy Now101.82%Needham
Ami Fadia
—Initiates → BuyGet Alert
08/16/2021Buy Now92.64%HC Wainwright & Co.
Oren Livnat
—MaintainsBuyGet Alert

FAQ

Q

What is the target price for Jazz Pharmaceuticals (JAZZ) stock?

A

The latest price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) was reported by Morgan Stanley on July 12, 2024. The analyst firm set a price target for $150.00 expecting JAZZ to rise to within 12 months (a possible 37.60% upside). 36 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Jazz Pharmaceuticals (JAZZ)?

A

The latest analyst rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) was provided by Morgan Stanley, and Jazz Pharmaceuticals maintained their equal-weight rating.

Q

When was the last upgrade for Jazz Pharmaceuticals (JAZZ)?

A

The last upgrade for Jazz Pharmaceuticals PLC happened on December 9, 2022 when Goldman Sachs raised their price target to $190. Goldman Sachs previously had a neutral for Jazz Pharmaceuticals PLC.

Q

When was the last downgrade for Jazz Pharmaceuticals (JAZZ)?

A

The last downgrade for Jazz Pharmaceuticals PLC happened on November 27, 2023 when UBS changed their price target from $170 to $135 for Jazz Pharmaceuticals PLC.

Q

When is the next analyst rating going to be posted or updated for Jazz Pharmaceuticals (JAZZ)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on July 12, 2024 so you should expect the next rating to be made available sometime around July 12, 2025.

Q

Is the Analyst Rating Jazz Pharmaceuticals (JAZZ) correct?

A

While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a maintained with a price target of $160.00 to $150.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $109.01, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch